WuXi AppTec Co., Ltd. Class H (HK:2359)
:2359
Want to see HK:2359 full AI Analyst Report?
2359 Stock Chart & Stats
HK$122.90
HK$1.65(3.23%)
At close: 4:00 PM EST
HK$122.90
HK$1.65(3.23%)
Day’s Range― - ―
52-Week RangeHK$64.65 - HK$148.00
Previous CloseN/A
Volume2.88M
Average Volume (3M)6.08M
Market Cap
HK$351.41B
Enterprise ValueHK$227.48B
Total Cash (Recent Filing)HK$43.38B
Total Debt (Recent Filing)HK$8.21B
Price to Earnings (P/E)16.2
Beta1.66
Next Earnings
Aug 03, 2026EPS Estimate
1.83Next Dividend Ex-DateN/A
Dividend Yield1.84%
Share Statistics
EPS (TTM)7.03
Shares Outstanding510,476,900
10 Day Avg. Volume5,559,442
30 Day Avg. Volume6,076,831
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)3.18
Price to Sales (P/S)5.57
P/FCF Ratio21.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$165.56Price Target Upside34.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)6.9
Revenue Forecast (FY)HK$60.94B
Bulls Say, Bears Say
Bulls Say
High Profitability And ReturnsWuXi’s structurally high margins and strong ROE indicate durable operating leverage and pricing power across its services. Sustained 40%+ net margins provide internal funding for capex, dividends and expansion, and create a margin cushion versus cyclic cost or pricing pressures.
Large Backlog And Revenue VisibilityA RMB 58bn backlog with ~70% expected conversion gives clear multi-quarter revenue visibility and supports capital allocation and hiring decisions. High backlog conversion reduces execution risk and underpins the company’s medium‑term revenue guidance and operational planning.
Capacity Buildout And Regulatory QualitySignificant capacity expansion and repeated FDA/OECD/NMPA/PMDA inspection success strengthen WuXi’s supply reliability and customer confidence. Scale plus regulatory compliance are durable competitive advantages for winning and retaining complex, long‑term CDMO and TIDES contracts.
Bears Say
Volatile Free Cash FlowDespite strong earnings, free cash flow has been volatile and fell sharply in the TTM period. Irregular FCF complicates funding of heavy capex, capacity buildouts and generous distributions without borrowing or asset sales, reducing financial flexibility over the medium term.
Rising Inventory And Working CapitalInventory rising faster than revenue ties up cash and creates timing risk in converting backlog to cash. For complex, long‑cycle manufacturing projects this can amplify working‑capital swings, pressure returns on capital, and increase vulnerability to demand timing shifts.
Concentration Risk In TIDES/peptidesRapid growth concentrated in TIDES/peptides and GLP‑1 exposes revenue to modality‑specific cycles or competitive disruption. If demand or pricing for these modalities slows after 2026, overall growth and margin expansion could be harder to sustain without clear diversification of growth drivers.
WuXi AppTec Co., Ltd. Class H News
2359 FAQ
What was WuXi AppTec Co., Ltd. Class H’s price range in the past 12 months?
WuXi AppTec Co., Ltd. Class H lowest stock price was HK$64.65 and its highest was HK$148.00 in the past 12 months.
What is WuXi AppTec Co., Ltd. Class H’s market cap?
WuXi AppTec Co., Ltd. Class H’s market cap is HK$351.41B.
When is WuXi AppTec Co., Ltd. Class H’s upcoming earnings report date?
WuXi AppTec Co., Ltd. Class H’s upcoming earnings report date is Aug 03, 2026 which is in 74 days.
How were WuXi AppTec Co., Ltd. Class H’s earnings last quarter?
WuXi AppTec Co., Ltd. Class H released its earnings results on Apr 27, 2026. The company reported HK$1.811 earnings per share for the quarter, beating the consensus estimate of HK$1.388 by HK$0.423.
Is WuXi AppTec Co., Ltd. Class H overvalued?
According to Wall Street analysts WuXi AppTec Co., Ltd. Class H’s price is currently Undervalued.
Does WuXi AppTec Co., Ltd. Class H pay dividends?
WuXi AppTec Co., Ltd. Class H pays a Annually dividend of HK$0.385 which represents an annual dividend yield of 1.84%. See more information on WuXi AppTec Co., Ltd. Class H dividends here
What is WuXi AppTec Co., Ltd. Class H’s EPS estimate?
WuXi AppTec Co., Ltd. Class H’s EPS estimate is 1.83.
How many shares outstanding does WuXi AppTec Co., Ltd. Class H have?
WuXi AppTec Co., Ltd. Class H has 510,476,900 shares outstanding.
What happened to WuXi AppTec Co., Ltd. Class H’s price movement after its last earnings report?
WuXi AppTec Co., Ltd. Class H reported an EPS of HK$1.811 in its last earnings report, beating expectations of HK$1.388. Following the earnings report the stock price went up 1.859%.
Which hedge fund is a major shareholder of WuXi AppTec Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2359
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
WuXi AppTec Co., Ltd. Class H Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
118.09%
12-Months-Change
Fundamentals
Return on Equity
28.07%
Trailing 12-Months
Asset Growth
34.36%
Trailing 12-Months
Company Description
WuXi AppTec Co., Ltd. Class H
WuXi AppTec Co., Ltd., an investment holding company, provides research, development, and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene therapies in the People's Republic of China, rest of Asia, the United States, Europe, and internationally. The company operates through six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions that support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides seamless drug and medical device testing services from preclinical testing to clinical trials; an integrated end-to-end solution to accelerate time to market for cell and gene therapies; drug discovery services to pharmaceutical and biotech customers; and clinical research services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.
2359 Stock 12 Month Forecast
Average Price Target
HK$165.56
▲(34.71% Upside)
Technical Analysis
Wuxi Biologics (Cayman)
―
Hangzhou Tigermed Consulting Co., Ltd. Class H
―
Pharmaron Beijing Co., Ltd. Class H
―
Hansoh Pharmaceutical Group Company Limited
―
WuXi XDC Cayman, Inc.
―
Options Prices
Currently, No data available
---